Last reviewed · How we verify
NCT06336096
A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of Suzetrigine
Phase 1 trial testing Suzetrigine in Pain in 48 participants. Completed in 19 June 2024.
19 June 2024
Quick facts
| Lead sponsor | Vertex Pharmaceuticals Incorporated |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 48 |
| Start date | 28 March 2024 |
| Primary completion | 19 June 2024 |
| Estimated completion | 19 June 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Suzetrigine (SUZETRIGINE) — full drug profile →
- Suzetrigine (SUZETRIGINE) — full drug profile →
Conditions studied
- Pain — all drugs for Pain →
Sponsor
Vertex Pharmaceuticals Incorporated — full company profile →
Who can join
Adults 18 to 55, any sex, with Pain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the pharmacokinetics (PK) of suzetrigine (SUZ; VX-548) and its metabolite along with its safety and tolerability, in healthy participants.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Suzetrigine, a Na<sub>V</sub>1.8 Inhibitor as a Novel Approach for Pain Therapy-A Medicinal and Chemical Drug Profile.
Medhat RM, Kotb OA, Baecker D. · · 2026 · cited 1× · PMID 41599406 · DOI 10.3390/molecules31020358
Verify or expand the search:
- PubMed search for NCT06336096
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Suzetrigine
Trials testing the same drug.
- NCT07511400 — The Role of NaV1.8 in Human Pain Models · EARLY_PHASE1 · not yet recruiting
- NCT07357376 — Evaluating Suzetrigine for Pain Control Following TKA · Phase 3 · not yet recruiting
- NCT07378865 — Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants · Phase 1 · recruiting
- NCT07231419 — Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy · Phase 3 · recruiting
- NCT07226700 — Suzetrigine in Total Hip Arthroplasty · Phase 3 · recruiting
Other recruiting trials for Pain
Currently open trials in the same condition.
- NCT07533409 — Tactile and Pain Sensory Thresholds and Hand Grip Strength · recruiting
- NCT07294092 — Ketamine and Propofol NeuroImaging · EARLY_PHASE1 · recruiting
- NCT07290205 — Remimazolam NeuroImaging · EARLY_PHASE1 · recruiting
- NCT07487610 — Relationship Between Neuropathic Pain and Geriatric Assessment Parameters in Patients Aged 80 Years and Older · recruiting
- NCT07454993 — The Effect of Music During Colonoscopy · NA · recruiting
Other Vertex Pharmaceuticals Incorporated trials
Trials by the same sponsor.
- NCT05951205 — Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/ βC Ge · Phase 3 · withdrawn
- NCT07501702 — A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis · Phase 2 · not yet recruiting
- NCT07437105 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants · Phase 1 · recruiting
- NCT07378865 — Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants · Phase 1 · recruiting
- NCT07349394 — Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06336096 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Vertex Pharmaceuticals Incorporated
- Last refreshed: 19 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06336096.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing